We are committed to advancing the treatment of eye conditions such as keratoconus and corneal ectasia following refractive surgery, through the continued innovation of our corneal cross-linking technology and pharmaceuticals. We develop products that are not only state-of-the-art but uphold the highest levels of quality and safety. Source
No articles found.
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthro...
Eyenovia is a late-stage ophthalmic biopharmace...
Corcept is a pharmaceutical company engaged in the discovery, development and comm...
Corcept is a pharmaceutical company engaged in ...
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Alder BioPharmaceuticals is a clinical-stage bi...
For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...
For more than 40 years, IntriCon has been meeti...
Join the National Investor Network and get the latest information with your interests in mind.